Optimizing the treatment of metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 89, Issue SUPPL., 2005, Pages

  Gralow, Julie R ^a  

^a Sch of Pub Hlth Comm Medicine   (United States)

Author keywords

Biologic therapy; Combination chemotherapy; Endocrine therapy; Metastatic breast cancer; Single agent chemotherapy

Indexed keywords

ANASTROZOLE; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIRUBICIN; ETOPOSIDE; EXEMESTANE; FULVESTRANT; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HORMONE; LETROZOLE; NAVELBINE; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAXANE DERIVATIVE; THIOTEPA; TOREMIFENE; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN;

ARTHRALGIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORRELATION ANALYSIS; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HAND FOOT SYNDROME; HORMONAL THERAPY; HUMAN; MULTIMODALITY CANCER THERAPY; MYALGIA; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; STOMATITIS; VOMITING;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS; DOWN-REGULATION; FEMALE; HUMANS; NEOPLASM METASTASIS; PROGNOSIS; QUALITY OF LIFE; RECEPTORS, ESTROGEN;

EID: 16844373011     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-0143-z     Document Type: Review

References (40)

1. National Comprehensive Cancer Network: Clinical practice guidelines in oncology: Breast cancer. Version 3: 2003
2. CT Chung RW Carlson 2003 Goals and objectives in the management of metastatic breast cancer Oncologist 8 514 520
3. J Bonneterre A Buzdar JM Nabholtz JF Robertson B Thürlimann M von Euler T Sahmoud A Webster M Steinberg 2001 Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma: results of two randomized trials designed for combined analysis Cancer 92 2247 2258
4. R Paridaens L Dirix C Lohrisch L Beex M Nooij D Cameron L Biganzoli T Cufer L Duchateau A Hamilton JP Lobelle M Piccart 2003 Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer Ann Oncol 14 1391 1398
5. H Mouridsen M Gershanovich Y Sun R Pérez-Carrión C Boni A Monnier J Apffelstaedt R Smith HP Sleeboom F Jaenicke A Pluzanska M Dank D Becquart PP Bapsy E Salminen R Snyder H Chaudri-Ross R Lang P Wyld A Bhatnagar 2003 Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J Clin Oncol 21 2101 2109
6. B Brun M Benchalal C Lebas P Piedbois M Lin JP Lebourgeois 1997 Response to second-line chemotherapy in patients with metastatic breast carcinoma previously responsive to first-line treatment: prognostic factors Cancer 79 2137 2146
7. Paridaens R, Therasse P, Dirix L, Beex L, Piccart M, Cameron D, Cufer T, Roozendaal K, Nooij M, Mattiacci M-R: First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group. J Clin Oncol 22(14S): 2004 (abstract 515)
8. A Howell JF Robertson J Quaresma Albano A Aschermannova L Mauriac UR Kleeberg I Vergote B Erikstein A Webster C Morris 2002 Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 3396 3403
9. A Howell JFR Robertson I Vergote L Mauriac UR Kleeberg J Quaresma Albano A Aschermannova 2003 Fulvestrant versus anastrozole for the treatment of advanced breast cancer: survival analysis from a phase III trial Proc Am Soc Clin Oncol 22 45 (abstract 178)
10. CK Osborne J Pippen SE Jones LM Parker M Ellis S Come SZ Gertler JT May G Burton I Dimery A Webster C Morris R Elledge A Buzdar 2002 Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial J Clin Oncol 20 3386 3395
11. A Howell JF Robertson P Abram MR Lichinitser R Elledge E Bajetta T Watanabe C Morris A Webster I Dimery CK Osborne 2004 Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial J Clin Oncol 22 1605 1613
12. KL Cheung JF Robertson 2002 Fulvestrant Expert Opin Investig Drugs 11 303 308
13. AD Seidman 2003 Monotherapy options in the management of metastatic breast cancer Semin Oncol 30 (2 Suppl 3) 6 10
14. EA Perez 1998 Paclitaxel in breast cancer Oncologist 3 373 389
15. DP Figgitt LR Wiseman 2000 Docetaxel: an update of its use in advanced breast cancer Drugs 59 621 651
16. E Rivera 2003 Liposomal anthracyclines in metastatic breast cancer: clinical update Oncologist 8 (Suppl 2) 3 9
17. R Paridaens L Biganzoli P Bruning JG Klijn T Gamucci S Houston R Coleman J Schachter A Van Vreckem R Sylvester A Awada J Wildiers M Piccart 2000 Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over J Clin Oncol 18 724 733
18. A Michelotti M Venturini C Tibaldi C Bengala L Gallo F Carnino L Del Mastro R Lionetto E Montanaro R Rosso P Conte 2000 Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients Breast Cancer Res Treat 59 133 139
19. M Bontenbal M Andersson J Wildiers G Cocconi J Jassem R Paridaens N Rotmensz R Sylvester HT Mouridsen JG Klijn AT van Oosterom 1998 Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group Br J Cancer 77 2257 2263
20. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485-493, 1999
21. Valerio MR, Cicero G, Armata MG, Bajardi E, Crosta A, Badalamenti G, Arcara C, Agosta G, Vieni S, Latteri F, Russo A, Gulotta G, Gebbia N: Gemcitabine (G) in pretreated breast cancer (BC). In: 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, USA, May 12-15, 2001 (abstract 1953)
22. RB Livingston GK Ellis JR Gralow MA Williams R White C McGuirt BB Adamkiewicz CA Long 1997 Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer J Clin Oncol 15 1395 1400
23. V Valero SE Jones DD Von Hoff DJ Booser RG Mennel PM Ravdin FA Holmes Z Rahman MW Schottstaedt JK Erban L Esparza-Guerra RH Earhart GN Hortobagyi HA Burris III 1998 A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer J Clin Oncol 16 3362 3368
24. M O'Brien N Wigler M Inbar R Rosso E Grischke A Santoro R Catane DG Kieback P Tomczak SP Ackland F Orlandi L Mellars L Alland C Tendler 2004 Reduced cardiotoxicity and comparable efficacy in a phase 3 trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann Oncol 15 440 449
25. T Safra 2003 Cardiac safety of liposomal anthracyclines Oncologist 8 (Suppl 2) 17 24
26. Gradishar WJ: The future of breast cancer: the role of prognostic factors. Breast Cancer Res Treat 89(Suppl 1): S17-S26, 2005
27. GW Sledge D Neuberg P Bernardo JN Ingle S Martino EK Rowinsky WC Wood 2003 Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) J Clin Oncol 21 588 592
28. J O'Shaughnessy D Miles S Vukelja V Moiseyenko JP Ayoub G Cervantes P Fumoleau S Jones WY Lui L Mauriac C Twelves G Van Hazel S Verma R Leonard 2002 Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results J Clin Oncol 20 2812 2823
29. Albain KS, Nag S, Calderillo-Ruiz G, Jordaan JP, Llombart A, Pluzanska A, Pawlicki M, Melemed AS, O'Shaughnessy J, Reyes JM: Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. J Clin Oncol 22(14S): 2004 (abstract 510)
30. Moinpour C, Wu J, Donaldson G, Liepa A, Melemed A, O'Shaughnessy J, Rappold E, Albain K: Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Quality of life (QoL) and pain palliation results from the global phase III study. J Clin Oncol 22(14S): 2004 (abstract 621)
31. D Miles G von Minckwitz AD Seidman 2002 Combination versus sequential single-agent therapy in metastatic breast cancer Oncologist 7 (Suppl 6) 13 19
32. MX Sliwkowski JA Lofgren GD Lewis TE Hotaling BM Fendly JA Fox 1999 Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) Semin Oncol 26 (4 Suppl 12) 60 70
33. M Pegram S Hsu G Lewis R Pietras M Beryt M Sliwkowski D Coombs D Baly F Kabbinavar D Slamon 1999 Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers Oncogene 18 2241 2251
34. MD Pegram A Lopez G Konecny DJ Slamon 2000 Trastuzumab and chemotherapeutics: drug interactions and synergies Semin Oncol 27 (6 Suppl 11) 21 25
35. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792
36. AC Wolff M Bonetti JA Sparano M Wang NE Davidson 2003 Cardiac safety of trastuzumab (H) in combination with pegylated liposomal doxorubicin (D) and docetaxel (T) in HER2-positive metastatic breast cancer (MBC): preliminary results of the Eastern Cooperative Oncology Group trial E3198 Proc Am Soc Clin Oncol 22 18 abstract 70
37. Theodoulou M, Campos SM, Batist G, Winer E, Norton L, Hudis C, Welles L: TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis. In: 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, USA, May 18-21, 2002 (abstract 216)
38. Trigo JM, Climent MA, Lluch A, Gascón P, Hornedo J, Gil M, Cirera L, Guillem V, Regueiro P, Baselga J: Liposomal doxorubicin (Myocet®) in combination with Herceptin® and paclitaxel, is active and well tolerated in patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC): a phase II study. In: 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 3-6, 2003 (abstract 351)
39. B Leyland-Jones K Gelmon JP Ayoub A Arnold S Verma R Dias P Ghahramani 2003 Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel J Clin Oncol 21 3965 3971
40. AS Langer 2001 Side effects, quality-of-life issues, and trade-offs: the patient perspective J Natl Cancer Inst Monogr 30 125 129